About Barts and The London School of Medicine and Dentistry
At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.
In 1785, Sir William Blizard established England’s first medical school, The London Hospital Medical College, to improve the health of east London’s inhabitants. Together with St Bartholomew’s Medical College, founded by John Abernethy in 1843 to help those living in the City of London, these two historic institutions are the bedrock of Barts and The London School of Medicine and Dentistry, Queen Mary’s faculty of Medicine and Dentistry.
Today, Barts and The London continues to uphold this commitment to pioneering medical education and research. Being firmly embedded within our east London community, and with an approach to education and research that is driven by the specific health needs of our diverse population, is what makes Barts and The London a truly distinctive School of Medicine and Dentistry.
Our heterogeneous local community offer to us a window to the world, ensuring that our ground-breaking research in cancer, cardiovascular and inflammatory diseases, and population health not only dramatically improves the outcomes for patients in London, but also has a far-reaching global impact.
Take, for example, our work on genomic and personalised medicine. East London Genes & Heath is a longitudinal study of 100,000 people of Bangladeshi and Pakistani ethnicity within the East London community. Through the analysis of this unique population, we are paving the way in the identification of genetic determinants for specific illnesses affecting this community. By working in partnership with our community, such studies are driving innovations in precision-based treatments for conditions such as heart disease and diabetes, transforming health outcomes locally and worldwide.
This is just one of the many ways in which Queen Mary is continuing to push the boundaries of teaching, research and clinical practice, and helping us to achieve the previously unthinkable.
- 2nd in London for Medicine – The Guardian University Guide 2020
- 2nd in London for Dentistry – The Guardian University Guide 2020
- 2ndin London for Medicine - The Complete University Guide 2020
- 2nd in London for Dentistry - The Complete University Guide 2020
- 3rdin the world for research citations – QS World University Rankings 2019
More about rankings and league tables.
National Student Survey (NSS) results – 2019
- 90 per cent overall student satisfaction
- Ranked 2nd in London
- 89 per cent overall student satisfaction
- Ranked 1st in London
Russell Group Member
Queen Mary University of London (QMUL) is one of 24 leading UK universities represented by the Russell Group that are committed to maintaining the very best research, an outstanding teaching and learning experience, excellent graduate employability and unrivalled links with business and the public sector.
Barts and The London School of Medicine and Dentistry is a faculty of QMUL. One of the leading medical schools in the UK, Barts and The London School of Medicine and Dentistry brings together two venerable teaching institutions: St Bartholomew's Hospital, which dates back to 1123, and The London Hospital Medical College, which was the first purpose-built medical school in England and Wales, founded in 1785.
This wealth of tradition is combined with some of the most modern medical facilities in the UK, including the largest new hospital in Europe, the first new dental hospital building in the UK for 40 years, and in the Blizard Building, some of the largest open-plan biomedical research laboratories in Europe.
As you would expect from a medical college that has 230 years experience of training the next generation of doctors and surgeons, our students are very satisfied with their learning experience – in the most recent National Student Survey (NSS 2018), 92 per cent were satisfied with the quality of their course. We will bringing the same standards of innovative research-led teaching and investment in excellent facilities to our MBBS in Malta.
Through partnership with our linked trusts, notably Barts Health NHS Trust, and our associated University Hospital Trusts – Homerton, Newham, Whipps Cross and Queen’s (Romford) the School’s research and teaching is informed by an exceptionally wide ranging and stimulating clinical environment.
According to the Research Excellence Framework (REF 2014) Barts and The London School of Medicine and Dentistry is placed within the top seven UK institutions in all three Units of Assessment – Clinical Medicine; Public Health, Health Services and Primary Care; and Allied Health Professions, Dentistry, Nursing and Pharmacy.
Research is focused on translational research, cancer, cardiac, dentistry, inflammation, endocrinology/ metabolism, immunology and infectious diseases, genomics, neuroscience, gastroenterology, epidemiology and primary care.
The School is nationally and internationally recognised for research in these areas, reflected in the £100 million it attracts annually in research income. Its fundamental mission, with its partner NHS Trusts, and other partner organisations, such as CR-UK, is to ensure that that the best possible clinical service is underpinned by the very latest developments in scientific and clinical teaching, training and research.
School of Medicine and Dentistry
Strategy - the next five years
Our aim for the next five years is to grow and to further improve our research, teaching and training excellence, impacting on local, national and international communities. We will contribute and enhance the success of QMUL as a vibrant Russell Group University.
To access the five-year strategy please visit the website.
The School is organised into the following Institutes:
- Barts Cancer Institute
- Blizard Institute of Cell and Molecular Science
- Institute of Health Sciences Education
- Institute of Dentistry
- William Harvey Research Institute
- Wolfson Institute of Preventive Medicine
More about our institutes
The School is also home to the first Cancer Research UK Clinical Centre to be established which takes an innovative 'molecules to patient' approach to research.